{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T20:58:28Z","timestamp":1694465908598},"reference-count":51,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T00:00:00Z","timestamp":1556150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>The aims of this study were to develop a pharmacokinetic (PK) and PK\u2010pharmacodynamic (PK\/PD) model of cinacalcet in adults and paediatrics with secondary hyperparathyroidism (SHPT) on dialysis, to test covariates of interest, and to perform simulations to inform dosing in paediatrics with SHPT.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Cinacalcet PK, intact parathyroid hormone (iPTH) and corrected calcium (cCa) time courses following multiple daily oral doses (1\u2013300\u00a0mg) were modelled using a nonlinear mixed effects modelling approach using data from eight clinical studies. Model\u2010based trial simulations, using adult or paediatric titration schemas, predicted efficacy (iPTH change from baseline and proportion achieving iPTH decrease \u226530%) and safety (cCa change from baseline and proportion achieving cCa \u22648.4\u00a0mg\/dL) endpoints at 24\u00a0weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cinacalcet PK parameters were described by a two\u2010compartment linear model with delayed first\u2010order absorption\u2010elimination (apparent clearance = 287.74\u00a0L\u00a0h<jats:sup>\u22121<\/jats:sup>). Simulations suggested that paediatric starting doses (1, 2.5, 5, 10 and 15\u00a0mg) would provide PK exposures less than or similar to a 30\u00a0mg adult dose. The titrated dose simulations suggested that the mean (prediction interval) proportion of paediatric and adult subjects achieving \u226530% reduction in iPTH from baseline at Week 24 was 49% (36%, 62%), and 70.1% (62.5%, 77%), respectively. Additionally, the mean (confidence interval) proportion of paediatric and adult subjects achieving cCa \u22648.4\u00a0mg\u00a0dL<jats:sup>\u22121<\/jats:sup> at Week 24 was 8% (2%, 18%) and 23.6% (17.5%, 30.5%), respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Model\u2010based simulations showed that the paediatric cinacalcet starting dose (0.2\u00a0mg\u00a0kg<jats:sup>\u22121<\/jats:sup>), titrated to effect, would provide the desired PD efficacy (PTH suppression &lt;30%) while minimizing safety concerns (hypocalcaemia).<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.13900","type":"journal-article","created":{"date-parts":[[2019,2,13]],"date-time":"2019-02-13T07:42:52Z","timestamp":1550043772000},"page":"1312-1325","source":"Crossref","is-referenced-by-count":3,"title":["Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic\u2010pharmacodynamic analysis of cinacalcet"],"prefix":"10.1111","volume":"85","author":[{"given":"Ping","family":"Chen","sequence":"first","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winnie","family":"Sohn","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adimoolam","family":"Narayanan","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per Olsson","family":"Gisleskog","sequence":"additional","affiliation":[{"name":"SGS Exprimo  London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murad","family":"Melhem","sequence":"additional","affiliation":[{"name":"Amgen Inc.  Thousand Oaks CA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2017.04.006"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0894-0959.2004.17308.x"},{"issue":"2","key":"e_1_2_9_4_1","first-page":"175","article-title":"Regulation of parathyroid hormone synthesis and secretion","volume":"14","author":"Silver J","year":"1994","journal-title":"Semin Nephrol"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.06040710"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422003"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ki.5002287"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2008.01.007"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2011.139"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2015020152"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00727.x"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.1999.14.10.1680"},{"issue":"12","key":"e_1_2_9_13_1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1681\/ASN.V3121938","article-title":"Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital","volume":"3","author":"Mathias R","year":"1993","journal-title":"J Am Soc Nephrol"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200305110-00005"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.05940611"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2012.12.017"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.2001.81.1.239"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(86)81427-2"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00866757"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/13.8.1923"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.103.057273"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.7.4040"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2005070679"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa031633"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200948050-00002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200544050-00004"},{"key":"e_1_2_9_27_1","unstructured":"Amgen Inc.Sensipar\u00ae(cinacalcet) prescribing information.2011."},{"key":"e_1_2_9_28_1","unstructured":"Amgen Inc.Sensipar\u00ae(cinacalcet) Summary of Product Characteristics.2018."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn186"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.199"},{"key":"e_1_2_9_31_1","unstructured":"National Center for Health Statistics.National Health and Nutrition Examination Survey 2009\u20132010. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?BeginYear=2009."},{"key":"e_1_2_9_32_1","unstructured":"Amgen Inc.Clinical Study Report: A phase 3 study to assess the efficacy and safety of an oral calcimimetic agent (AMG 073) in secondary hyperparathyroidism of end stage renal disease treated with hemodialysis.2003."},{"key":"e_1_2_9_33_1","unstructured":"Amgen Inc.Clinical Study Report: A randomized double\u2010blind placebo\u2010controlled study to assess the efficacy and safety of cinacalcet HCl in pediatric subjects with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.2016."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347181"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkx1121"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13878"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1357-2725(00)00031-5"},{"issue":"2","key":"e_1_2_9_38_1","first-page":"187","article-title":"Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods","volume":"33","author":"Ehlert FJ","year":"1988","journal-title":"Mol Pharmacol"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1098\/rspb.1983.0093"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.08.053"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.204834"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12106"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.11.236"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0134-5"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2002-011870"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270011412967"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.109.152033"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(99)70120-7"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-011-9266-9"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0550-4"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-8011-3_2"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbcp.13900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.13900","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.13900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T07:11:57Z","timestamp":1694329917000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.13900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/bcp.13900"],"URL":"https:\/\/doi.org\/10.1111\/bcp.13900","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]}}}